{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:12:27Z","timestamp":1767989547670,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":2052,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Taiho Pharmaceuticals, Co., Ltd."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.jpainsymman.2013.07.006","type":"journal-article","created":{"date-parts":[[2013,10,5]],"date-time":"2013-10-05T03:07:04Z","timestamp":1380942424000},"page":"990-1000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A Randomized, Double-Blind, Placebo-Controlled Study of Fentanyl Buccal Tablets for Breakthrough Pain: Efficacy and Safety in Japanese Cancer Patients"],"prefix":"10.1016","volume":"47","author":[{"given":"Toshifumi","family":"Kosugi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasagu","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chizuko","family":"Takigawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kunikane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Tanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Shima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinomi","family":"Yomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Matoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isamu","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsusuke","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2013.07.006_bib1","series-title":"Disease control priorities in developing countries","first-page":"981","article-title":"Pain control for people with cancer and AIDS","author":"Foley","year":"2006"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0304-3959(99)00006-8","article-title":"Breakthrough pain: characteristics and impact in patients with cancer pain","volume":"81","author":"Portenoy","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0304-3959(02)00293-2","article-title":"Cancer breakthrough pain characteristics and responses to treatment at a VA medical center","volume":"101","author":"Hwang","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5055\/jom.2010.0009","article-title":"Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics","volume":"6","author":"Portenoy","year":"2010","journal-title":"J\u00a0Opioid Manag"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(90)90004-W","article-title":"Breakthrough pain: definition, prevalence and characteristics","volume":"41","author":"Portenoy","year":"1990","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0885-3924(00)00161-5","article-title":"Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice","volume":"20","author":"Zeppetella","year":"2000","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib7","first-page":"296","article-title":"Consensus panel recommendations for the assessment and management of breakthrough pain. Part 1: assessment","volume":"30","author":"Bennett","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib8","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib9","first-page":"354","article-title":"Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: management","volume":"30","author":"Bennett","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0305-7372(98)90005-6","article-title":"Breakthrough pain in cancer patients: pathophysiology and treatment","volume":"24","author":"Mercadante","year":"1998","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib11","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1185\/03007990903368310","article-title":"Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain","volume":"25","author":"Rauck","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jnci\/90.8.611","article-title":"Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients","volume":"90","author":"Farrar","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib13","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/annonc\/mdp541","article-title":"Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study","volume":"21","author":"Rauck","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib14","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/jjco\/hyh104","article-title":"Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets","volume":"34","author":"Koizumi","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib15","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.ajp.0000210932.27945.4a","article-title":"A\u00a0randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer","volume":"22","author":"Portenoy","year":"2006","journal-title":"Clin J Pain"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib16","first-page":"327","article-title":"Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain","volume":"5","author":"Slatkin","year":"2007","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/0269216309356138","article-title":"Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study","volume":"24","author":"Lennern\u00e4s","year":"2010","journal-title":"Palliat Med"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00002508-200405000-00011","article-title":"Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises: a retrospective case series","volume":"20","author":"Burton","year":"2004","journal-title":"Clin J Pain"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib19","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.1998.16.10.3238","article-title":"Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain","volume":"16","author":"Christie","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0304-3959(98)00179-1","article-title":"Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study","volume":"79","author":"Portenoy","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0304-3959(00)00427-9","article-title":"Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR)","volume":"91","author":"Coluzzi","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib22","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.clinthera.2009.05.022","volume":"31","author":"Kress","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib23","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00000542-199503000-00018","article-title":"Buccal absorption of fentanyl is pH-dependent in dogs","volume":"82","author":"Streisand","year":"1995","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib24","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1023\/A:1011936901638","article-title":"Mechanistic studies on effervescent-induced permeability enhancement","volume":"15","author":"Eichman","year":"1998","journal-title":"Pharm Res"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00137696-200604010-00001","article-title":"Fentanyl effervescent buccal tablets","volume":"4","author":"Durfee","year":"2006","journal-title":"Am J Drug Deliv"},{"key":"10.1016\/j.jpainsymman.2013.07.006_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1358\/dot.2008.44.1.1178469","article-title":"Fentanyl buccal tablet","volume":"44","author":"Messina","year":"2008","journal-title":"Drugs Today (Barc)"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392413004703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392413004703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:11:14Z","timestamp":1760130674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392413004703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0885392413004703"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.07.006","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized, Double-Blind, Placebo-Controlled Study of Fentanyl Buccal Tablets for Breakthrough Pain: Efficacy and Safety in Japanese Cancer Patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}